{"id":"W4311734051","doi":"10.1097/ccm.0000000000005716","title":"Astegolimab or Efmarodocokin Alfa in Patients With Severe COVID-19 Pneumonia: A Randomized, Phase 2 Trial*","year":2022,"lang":"en","type":"article","venue":"Critical Care Medicine","topic":"IL-33, ST2, and ILC Pathways","field":"Immunology and Microbiology","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Discovery Centre","funders":"","keywords":"Medicine; ARDS; Clinical endpoint; Pneumonia; Placebo; Randomized controlled trial; Internal medicine; Adverse effect; Cytokine release syndrome; Hazard ratio; Immunology; Lung; Coronavirus disease 2019 (COVID-19); Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008562963,0.0003217285,0.001189429,0.0002494611,0.0004220114,0.000008812636,0.0003057963,0.0001731447,0.003817945],"category_scores_gemma":[0.006295366,0.0002076179,0.0001068527,0.0004392408,0.001053887,0.00007488306,0.0001744982,0.0008067835,0.00005862927],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002973094,"about_ca_system_score_gemma":0.0005287593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003587192,"about_ca_topic_score_gemma":0.0001379217,"domain_scores_codex":[0.9965935,0.001367343,0.0006331651,0.0005531292,0.0002161784,0.0006366695],"domain_scores_gemma":[0.9972253,0.0019382,0.00008858759,0.0003962687,0.000199454,0.0001521902],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9787881,0.001309449,0.00140479,0.0003586252,0.0001308033,0.0004181398,0.006518291,0.000005717683,0.0003678222,0.001961917,0.006307815,0.002428525],"study_design_scores_gemma":[0.883632,0.00823972,0.000167502,0.0000657073,0.0002801225,0.0001348174,0.007774612,0.000002350962,0.00006301316,0.000245447,0.09907456,0.0003201113],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9705329,0.003899896,0.0004051717,0.006201663,0.003671787,0.004373852,0.00419033,0.0002131553,0.006511271],"genre_scores_gemma":[0.9938768,0.00002132,0.00002201483,0.003558603,0.0001285571,0.0005088071,0.001209776,0.00003351553,0.0006406649],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09515607,"threshold_uncertainty_score":0.9970927,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02216302880472214,"score_gpt":0.3117859823458574,"score_spread":0.2896229535411353,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}